Health and Healthcare
Dendreon Raising $125 Million Via I.P. Sale (DNDN, MRK)
Published:
Last Updated:
Now the company has news out that it has agreed to sell its royalty interest related to intellectual property licensed to Merck & Co. Inc. (NYSE: MRK) associated with VICTRELIS under the Schering unit for $125 million in cash.
VICTRELIS is a treatment for chronic hepatitis C as a protease inhibitor. The press release noted that the royalty interest was acquired by CPPIB Credit Investments Inc., a wholly-owned subsidiary of CPP Investment Board (CPPIB).
The intellectual property related to VICTRELIS was co-developed by Corvas International, Inc. and Schering and, was acquired by Dendreon in July 2003. The transaction is expected to close in December 2011.
The move is aimed at strengthening its cash position and to enable the company to further invest in its core business initiatives.
Dendreon shares are flat at $8.80 and its market cap is currently $1.3 billion. To show how bad this one has been, Dendreon’s 52-week trading range is $6.46 to $43.96.
JON C. OGG
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
